Abbvie (ABBV)
NYSE:ABBV
Want to see ABBV full AI Analyst Report?
ABBV Stock Chart & Stats
$208.38
-$1.97(-1.10%)
At close: 4:00 PM EST
$208.38
-$1.97(-1.10%)
Day’s Range― - ―
52-Week Range$181.73 - $244.81
Previous CloseN/A
Volume1.02M
Average Volume (3M)5.99M
Market Cap
$397.44B
Enterprise Value$447.89B
Total Cash (Recent Filing)$9.39B
Total Debt (Recent Filing)$72.86B
Price to Earnings (P/E)109.7
Beta0.19
Next Earnings
Jul 24, 2026EPS Estimate
3.76Next Dividend Ex-DateN/A
Dividend Yield2.87%
Share Statistics
EPS (TTM)2.04
Shares Outstanding1,766,792,800
10 Day Avg. Volume5,648,914
30 Day Avg. Volume5,990,219
Financial Highlights & Ratios
PEG Ratio-77.01
Price to Book (P/B)-124.40
Price to Sales (P/S)6.65
P/FCF Ratio22.83
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue7.13
Enterprise Value/Gross Profit10.09
Enterprise Value/Ebitda26.47
Forecast
1Y Price Target
$256.47Price Target Upside23.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)14.24
Revenue Forecast (FY)$67.28B
Bulls Say, Bears Say
Bulls Say
Cash-generation StrengthAbbVie’s large, growing free cash flow (TTM ~ $20.9B, +11.6%) is a durable structural strength: it funds R&D, manufacturing buildouts, dividends and BD activity without reliance on near-term equity or asset sales. Strong cash conversion supports strategic flexibility over coming quarters.
Immunology Commercial MomentumRapid, sustainable growth in Skyrizi and Rinvoq indicates successful portfolio transition as Humira wanes. Durable uptake across psoriasis, IBD and other indications underpins revenue resiliency and reduces concentration risk over the next 2–6 months as launches and label expansions progress.
Pipeline Progress And Capacity InvestmentRegulatory submissions, positive interim data and parallel manufacturing investments are structural positives: they expand future addressable markets and reduce launch bottlenecks. Combined clinical and capacity progress improves probability of durable commercial ramp for new indications.
Bears Say
Heavy LeverageVery high absolute and relative debt levels materially constrain strategic flexibility: interest and refinancing risk rise, credit-sensitive spends become harder to scale, and management’s capital allocation (M&A, buybacks) faces limits if earnings dip over the next several quarters.
Compressed Net MarginsSharp fall in net margin versus prior years signals persistent non-operating costs, acquired IPR&D impacts, and price/competitive pressure. Lower bottom-line elasticity reduces cushion for earnings shocks and weakens ability to deleverage quickly even with strong cash flow.
HUMIRA Biosimilar ErosionContinued Humira revenue decline from biosimilar entry is a structural headwind to near-term revenue stability. The transition places pressure on absolute top-line levels and increases reliance on ramping newer franchises to replace lost scale within the next 2–6 months.
AbbVie News
ABBV FAQ
What was Abbvie’s price range in the past 12 months?
Abbvie lowest stock price was $181.73 and its highest was $244.81 in the past 12 months.
What is Abbvie’s market cap?
Abbvie’s market cap is $397.44B.
When is Abbvie’s upcoming earnings report date?
Abbvie’s upcoming earnings report date is Jul 24, 2026 which is in 42 days.
How were Abbvie’s earnings last quarter?
Abbvie released its earnings results on Apr 29, 2026. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.592 by $0.058.
Is Abbvie overvalued?
According to Wall Street analysts Abbvie’s price is currently Undervalued.
Does Abbvie pay dividends?
Abbvie pays a Quarterly dividend of $1.73 which represents an annual dividend yield of 2.87%. See more information on Abbvie dividends here
What is Abbvie’s EPS estimate?
Abbvie’s EPS estimate is 3.76.
How many shares outstanding does Abbvie have?
Abbvie has 1,766,792,800 shares outstanding.
What happened to Abbvie’s price movement after its last earnings report?
Abbvie reported an EPS of $2.65 in its last earnings report, beating expectations of $2.592. Following the earnings report the stock price went up 3.136%.
Which hedge fund is a major shareholder of Abbvie?
Currently, no hedge funds are holding shares in ABBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$256.47 (23.08% Upside)
$256.47 (23.08% Upside)
Blogger Sentiment
Bullish
ABBV Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 8.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.57%
12-Months-Change
Fundamentals
Return on Equity
68.01%
Trailing 12-Months
Asset Growth
0.22%
Trailing 12-Months
Company Description
Abbvie
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
ABBV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and financial performance with multiple product growth drivers (Skyrizi, Rinvoq, neuroscience portfolio) and a raised full-year outlook. Substantial pipeline progress (regulatory submissions, combination Crohn's data, obesity signal) and major manufacturing investments reinforce long-term growth positioning. Offsets include expected HUMIRA biosimilar erosion, pressure in some oncology and aesthetic segments, selected clinical setbacks/non-differentiation and near-term acquired IPR&D expense impacts. On balance, highlights — including robust sales beats, double-digit growth for key franchises, guidance raise, and encouraging pipeline readouts — outweigh the lowlights.View all ABBV earnings summariesABBV Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
ABBV Stock 12 Month Forecast
Average Price Target
$256.47
▲(23.08% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
20.68% Mutual Funds
14.64% Other Institutional Investors
41.36% Public Companies and Individual Investors